SJR 10 Nevada Senate · 2025 Regular Session

Urges Congress to take certain actions relating to the therapeutic use of certain psychedelic compounds. (BDR R-801)

SJR 10 is a non-binding resolution urging Congress to take action supporting the therapeutic use of specific psychedelic compounds like psilocybin, MDMA, and ibogaine for mental health conditions. It cites FDA Breakthrough Therapy designations and clinical trial results showing promising outcomes for treatment-resistant depression, PTSD, and chronic pain. The resolution specifically references studies demonstrating significant symptom reduction in veterans and patients with mental health disorders. It does not create new laws or regulations but calls on federal lawmakers to advance research and access for these treatments.

Issues: ✓ Healthcare ✓ Veterans

Bill status passed both 4 of 5 stages cleared

Introduction

Feb 2025

Committee Review

May 2025

Senate Passage

Apr 2025

Assembly Passage

May 2025

Governor

Introduced Feb 26, 2025 Last action Jun 1, 2025

Maddy AI version diff · 3 comparisons

What changed between versions

Reprint 2 → As Enrolled · 5 edits

MODERATE

The bill was finalized for enrollment, removing internal committee and reprint metadata while streamlining the list of sponsors. The core policy content was significantly expanded to include new arguments about the safety profile of psychedelics, the barriers of Schedule I classification, and the existence of dedicated research centers at major universities.

Scope change

The bill's scope was broadened to address the legal and regulatory obstacles (specifically Schedule I status) preventing access to these treatments, in addition to urging Congress to act on therapeutic potential.

SCOPE

Added new arguments stating that Schedule I classification creates unnecessary research barriers and that physicians cannot legally use these substances for terminal patients under the Right to Try Act.

Included evidence from leading medical institutions (e.g., Johns Hopkins, Stanford) that have established dedicated centers for psychedelic research.

Added a new clause asserting that psychedelics have a favorable safety profile with no lasting neuropsychological deficits or organ damage.

TECHNICAL

Removed internal legislative markings, including the 'Reprint 2' header, committee referral notes, and line-numbered explanatory text.

Reformatted the list of joint sponsors to remove line numbers and adjust spacing for the final enrolled version.

Floor votes

How they voted

This bill passed the Senate by voice vote (no roll call recorded).

Full legislative history

Actions timeline

Total actions

Key actions

Committee

Amendments

May 29, 2025

Lower · Passed

Concur in Assembly Amendment No. 555. To enrollment.

lower

May 22, 2025

Lower · Passed

Resolution read. Passed, as amended. Title approved. Preamble adopted. (Yeas: 36, Nays: 6.) To Senate. In Senate.

lower

May 15, 2025

Introduced

Resolution read. Amended. (Amend. No. 555.) To printer.

lower

May 14, 2025

Lower · Passed

From committee: Amend, and do pass as amended.

lower

Apr 24, 2025

Committee

In Assembly. Resolution read. Referred to Committee on Legislative Operations and Elections. To committee.

lower

Apr 18, 2025

Upper · Passed

Resolution read. Passed, as amended. Title approved. Preamble adopted, as amended. (Yeas: 18, Nays: 2, Absent: 1.) To printer.

upper

Apr 17, 2025

Upper · Passed

From committee: Amend, and do pass as amended. Placed on Resolution File. Resolution read. Amended. (Amend. No. 346.) Reprinting dispensed with.

upper

Feb 27, 2025

Upper · Passed

From printer. To committee.

upper

Feb 26, 2025

Committee

Resolution read. Referred to Committee on Legislative Operations and Elections. To printer.

upper

6 primary · 20 co-sponsors